01—Abstract
Summary
Summary of the 10-K filed February 10, 2023. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' FY2022 10-K shows a company whose growth is almost entirely driven by cystic fibrosis (CF).
Net product revenues rose 18% to $8.93 billiona, led by TRIKAFTA/KAFTRIO, which generated $7.69 billion (up 35%). Operating income more than doubled from a year earlier to $4.31 billion, though that comparison is flattered by the $900 million CRISPR upfront payment booked in 2021. Net income reached $3.32 billion, or $12.82 per diluted share, up from $9.01.
Operating cash flow was $4.13 billionb, and cash and marketable securities grew to $10.8 billion. Investors should note that the four CF medicines still account for virtually all product revenue, and that the older CF products (ORKAMBI, SYMDEKO/SYMKEVI, KALYDECO) are declining as patients switch to TRIKAFTA. The pipeline is the main source of optionality.
Key programs include exa-cel (CRISPR-based gene editing for sickle cell disease and beta thalassemia, with a BLA in rolling submission), VX-548 (a non-opioid NaV1.8 pain candidate in Phase 3), inaxaplin (APOL1-mediated kidney disease, Phase 2/3), and VX-880 (stem-cell-derived islet cells for type 1 diabetes). The next-generation triple combination vanzacaftor/tezacaftor/deutivacaftor is in Phase 3, with data expected by the end of 2023. Management plans significant increases in R&D and SG&A spending in 2023 to prepare for these launches, which will pressure near-term margins.
Balance-sheet strength supports this, and the board approved a new $3.0 billionc share repurchase program in February 2023. The risk profile is concentrated. Substantially all revenue depends on CF, and a meaningful portion depends on the U.S. Inflation Reduction Act's Medicare drug price negotiation, along with ex-U.S. reimbursement timing.
Customer concentration is high: McKesson accounted for 25%d of gross product revenue. Patent litigation over KALYDECO generics is set for trial in 2024.
A large uncertain tax liability rose sharply in 2022, and the effective tax rate increased to 21.5% from 14.2%. Pipeline setbacks, including the discontinuation of VX-814 in 2020 and the hold on the U.S. IND for VX-264, remain material execution risks.
02—Key points
Key Highlights
- Total revenue rose 18% to $8.93B in 2022, with TRIKAFTA/KAFTRIO contributing $7.69B (up 35%) and reaching more than 30 countries outside the U.S.
- Net income increased 42% to $3.32B ($12.82 diluted EPS), supported by higher product revenue and a 2021 base that included a $900M CRISPR upfront charge.
- Operating cash flow of $4.13B and cash plus marketable securities of $10.8B (up from $7.5B) provide substantial financial flexibility.
- Ex-U.S. revenue grew 41% to $3.23B, showing that international reimbursement and launches are now a major growth driver.
- Late-stage pipeline includes exa-cel (sickle cell and beta thalassemia, BLA in rolling review), VX-548 (non-opioid pain, Phase 3), inaxaplin (AMKD, Phase 2/3), and a next-gen CF triple combination in Phase 3 with data expected by end-2023.
- Concentration risk remains high: all product revenue comes from CF medicines, McKesson represents 25% of gross product revenue, and the Inflation Reduction Act introduces future Medicare price negotiation.
- Management expects R&D, SG&A, and cost of sales to rise in 2023 to support launches, and a new $3.0B share repurchase program was authorized in February 2023.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2022, Vertex Pharmaceuticals Inc kept $0.37.
- Revenue$8.93B100.0%
- Cost of revenue−$1.08B12.1%
- Gross profit$7.85B87.9%
- Operating costs−$3.54B39.7%
- Operating income$4.31B48.2%
- Interest, other & tax−$985.4M11.0%
- Net income$3.32B37.2%
Where FY2022 revenue went
$8.93B- Net income: $3.32B, 37% of revenue
- Other operating costs: $2.60B, 29% of revenue
- Cost of revenue: $1.08B, 12% of revenue
- SG&A: $944.7M, 11% of revenue
- Interest, other & tax: $985.4M, 11% of revenue
Kept 37% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 10, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $8.93B$7.57B | +17.9% |
| Cost of Revenue | $1.08B$904.20M | +19.5% |
| Gross Profit | $7.85B$6.67B | +17.7% |
| SG&A Expenses | $944.70M$840.10M | +12.5% |
| Operating Expenses | $4.62B$4.79B | −3.5% |
| Operating Income | $4.31B$2.78B | +54.8% |
| Net Income | $3.32B$2.34B | +41.8% |
| EPS (Basic) | $12.97$9.09 | +42.7% |
| EPS (Diluted) | $12.82$9.01 | +42.3% |
| Shares Outstanding (Basic) | 256.10M257.70M | −0.6% |
| Shares Outstanding (Diluted) | 259.10M259.90M | −0.3% |
05—Questions
Frequently Asked Questions
How dependent is Vertex on its cystic fibrosis medicines?
Almost entirely. All product revenues and the vast majority of total revenues come from the four CF medicines, with TRIKAFTA/KAFTRIO accounting for about 86% of 2022 product revenue. This concentration is a central risk, so the company's pipeline progress outside CF is key to diversifying the business over time.
What drove the increase in 2022 profitability?
Net product revenue rose $1.4B, with the TRIKAFTA/KAFTRIO launches and steady U.S. performance driving the gain. Total costs and expenses fell 4% to $4.62B, mainly because acquired IPR&D dropped from $1.1B in 2021 (which included the $900M CRISPR payment) to $115.5M. R&D expenses rose 31%, partly offsetting these gains.
What are the key near-term catalysts for investors?
Key catalysts include completion of the FDA rolling BLA for exa-cel in Q1 2023, Phase 3 data for the vanzacaftor triple combination (SKYLINE 102/103) by the end of 2023, Phase 3 readouts for VX-548 in late 2023 or early 2024, and regulatory filings for younger children on TRIKAFTA/KAFTRIO. The KALYDECO generic patent trial is scheduled for February 2024.
What policy and reimbursement risks could affect future revenue?
The Inflation Reduction Act authorizes Medicare to negotiate maximum fair prices for certain drugs starting in 2026, and it changes Part D discount structures from 2025. Ex-U.S. governments are also pushing for lower prices and cost-effectiveness reviews, and reimbursement has previously lagged in some markets, such as England for ORKAMBI. Management has said it cannot predict the final financial impact.
Is the balance sheet sufficient to fund the pipeline and shareholder returns?
Yes, at least in the near term. Vertex held $10.8B in cash and marketable securities, a $500M undrawn revolving credit facility, and $4.1B in operating cash flow. Management believes these resources will fund operations for at least 12 months. The board also approved a $3.0B share repurchase program in February 2023, with repurchases to be funded from cash on hand and operating cash flow.
06—Continue